Dr. Gillis Tirzepatide Review: Maine Pricing and Adjunct Claims

Dr. Gillis' Wellness Center lists tirzepatide starting at $300 per month for eligible patients at its Oakland, Maine clinic. Its medication page describes no contracts and complimentary consultations on Wednesdays from 1–6 p.m.¹

The same page advertises retatrutide as an additional $100 monthly treatment alongside semaglutide or tirzepatide. That is a separate, material concern: FDA states retatrutide cannot be used in compounding under federal law and has not been found safe and effective for any condition.¹³ This review describes the published offer; it does not endorse that adjunct or establish firsthand treatment experience.

A local clinic, not verified nationwide shipping

The current medication page expressly says tirzepatide is available at the Central Maine location and gives an Oakland address. The FAQ likewise identifies a local option for patients seeking tirzepatide.¹²

Do not turn a clinic appointment invitation into a claim of nationwide telehealth availability. Ask whether the initial evaluation and later visits are in person, whether travel is required for refills and who provides continuing care. Local access can be useful if you prefer face-to-face support, but the actual appointment arrangement should be established before making plans.

The clinic's general medication explanations do not independently verify staff credentials, a particular patient's clinical eligibility or the quality of dispensed medicine. Those are separate questions from whether a current named product is advertised.

What $300 per month establishes

The medication page assigns the starting amount to tirzepatide rather than to the semaglutide or oral GLP-1 menu. It does not establish a complete dose ladder, formulation, quantity or all-dose guarantee at that amount.¹

Ask for the final prescription quote, including weekly milligrams, days supplied, vial count, required tests and clinical visits. Confirm whether the displayed amount applies only to an entry dose, whether later escalation changes the charge and whether dispensing supplies are included. A starting headline is useful for screening a program, but insufficient for a full treatment budget.

The clinic says it does not accept or bill insurance directly and accepts HSA/FSA cards. Its FAQ describes a cash-payment discount for semaglutide and tirzepatide.¹² Verify current eligibility and final cost rather than subtracting a discount automatically or assuming it can be combined with another promotion.

No contract does not settle refunds

The page's no-contract language may be relevant to a patient avoiding a long commitment, but it does not establish a refund for an already completed consultation or dispensed prescription.¹ Obtain the current appointment, cancellation and medication-refund policies before paying.

Ask what happens if the clinician decides treatment is unsuitable, if a dose changes after medicine has been supplied or if an order arrives damaged. Keep the written quote and receipt. A complimentary consultation window is different from a promise that all subsequent visits or laboratory work are free.

The retatrutide promotion requires a separate warning

The clinic's page offers adding retatrutide to an existing semaglutide or tirzepatide regimen. We do not treat its stated study benefits as proof that a combined clinic-supplied regimen is safe or effective.¹

FDA's current GLP-1 safety page specifically states retatrutide cannot be used in compounding under federal law. It also explains that retatrutide is not an ingredient in an FDA-approved drug and has not been found safe and effective for any condition.³ Do not read the clinic's offer as an approved treatment option or as an evidence-based way to enhance tirzepatide.

This is an observed marketing concern, not a claim that FDA has issued this particular clinic a warning letter. We did not establish a clinic-specific enforcement action, recall or closure. The distinction matters when stating what the sources actually show.

Verify the actual prescription and dispenser

The inspected tirzepatide listing does not identify the individual patient's pharmacy, precise formulation or dispensing instructions. Ask for those details, including the legal pharmacy name, contact information and authorization to dispense to you.

If a compounded product is proposed, understand that it is not FDA-approved. Trials of approved tirzepatide do not independently establish the performance of a particular compound, and the addition of another investigational ingredient requires its own evidence and regulatory assessment.³ Ask the clinician to explain approved alternatives and avoid using a marketing chart as a self-directed dosing plan.

Our assessment

The clinic publishes a real local tirzepatide starting offer and useful payment information. The incomplete dose-and-supply quote and the separate retatrutide promotion are material limitations. A cautious comparison should establish the exact medicine and exclude unverified adjunct claims from any purchasing rationale.

Compare other provider reviews, approved Zepbound costs and the retatrutide evidence guide when discussing options with a licensed clinician.

To compare what a clinic-based quote includes beyond the medication headline, see Chronos and Better Med Spa.